ID: ALA1950798

Max Phase: Preclinical

Molecular Formula: C18H16N2O7

Molecular Weight: 372.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1ccc2cc(C(=O)N3CCN[C@H](C(=O)O)[C@@H]3C(=O)O)ccc2c1

Standard InChI:  InChI=1S/C18H16N2O7/c21-15(20-6-5-19-13(17(24)25)14(20)18(26)27)11-3-1-10-8-12(16(22)23)4-2-9(10)7-11/h1-4,7-8,13-14,19H,5-6H2,(H,22,23)(H,24,25)(H,26,27)/t13-,14+/m0/s1

Standard InChI Key:  GOFFUPQTVAPLMS-UONOGXRCSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 372.33

Molecular Weight (Monoisotopic): 372.0958

AlogP: 0.49

#Rotatable Bonds: 4

Polar Surface Area: 144.24

Molecular Species: ACID

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.44

CX Basic pKa: 7.81

CX LogP: -1.61

CX LogD: -8.17

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.61

Np Likeness Score: -0.20

References

1. Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE..  (2012)  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.,  55  (1): [PMID:22111545] [10.1021/jm201230z]

Source

Source(1):

• Scientific Literature